Exenatide

History matters here. Exenatide proved the entire GLP-1 class worked in humans and opened the door to liraglutide, semaglutide and tirzepatide. But because exendin-4 is not a human peptide, a meaningful fraction of patients develop anti-drug antibodies, and the cardiovascular outcomes trial (EXSCEL, 2017) showed only a modest, non-significant benefit on the primary endpoint, while semaglutide (SUSTAIN-6) and liraglutide (LEADER) both showed clear MACE reduction. That is the main reason exenatide is now a third- or fourth-line choice in most guidelines rather than first-line within the class.

The evidence base for glycaemic efficacy is solid. The Byetta AMIGO programme (three pivotal 30-week Phase 3 trials, published in Diabetes Care 2004 to 2005 by DeFronzo, Buse and Kendall) showed HbA1c reductions of roughly 0.8 to 0.9 percentage points on top of metformin and / or sulfonylurea. The Bydureon DURATION programme then established that the once-weekly extended-release formulation was at least as effective as twice-daily Byetta, and in DURATION-6 (Buse et al., Lancet 2013) Bydureon produced a smaller HbA1c reduction than once-daily liraglutide (1.28% vs 1.48%). The head-to-head LEAD-6 trial (Buse et al., Lancet 2009) showed once-daily liraglutide also outperformed twice-daily Byetta on HbA1c. For cardiovascular outcomes, EXSCEL (Holman et al., NEJM 2017) is the definitive trial: 14,752 patients with type 2 diabetes, median 3.2 years, primary MACE HR 0.91 (95% CI 0.83 to 1.00; p=0.06 for superiority, p<0.001 for non-inferiority). So exenatide is safe cardiovascularly, but the effect size on MACE is smaller and less certain than for semaglutide or liraglutide. Honest caveats: the AMIGO and DURATION trials were sponsor-run (Amylin / Eli Lilly / AstraZeneca), and antibody formation introduces a real-world response heterogeneity that the headline averages mask.

For information only. This is a prescription medicine and dosing must be set by a clinician, not by reading a webpage. Byetta is a twice-daily subcutaneous injection given within 60 minutes before the morning and evening meals, starting at 5 micrograms twice daily for at least one month, with optional escalation to 10 micrograms twice daily. Bydureon is a once-weekly subcutaneous injection of 2 mg, given on the same day each week regardless of meals; steady-state plasma concentrations take about 6 to 7 weeks to develop after the first dose, so the full effect (and any peak side effects) lag. Self-dosing from unregulated suppliers is unsafe: the products are unverified, the antibody-formation risk is real, the gastrointestinal side-effect profile is significant during initiation, and prescriber oversight catches the contraindications below.

The commonest side effects are gastrointestinal: nausea (very common, particularly during Byetta initiation), vomiting, diarrhoea and constipation. Nausea is dose-related and tends to ease over weeks. Injection-site nodules are common with Bydureon (a recognised feature of the microsphere depot). More serious risks on the label include acute pancreatitis (post-marketing reports prompted an FDA label change in 2007 to 2008), acute kidney injury (usually mediated by dehydration from vomiting), and severe hypoglycaemia when combined with a sulfonylurea or insulin. The FDA label for Bydureon carries a boxed warning for thyroid C-cell tumours based on rodent data, and the medicine is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Exenatide is contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). Not for use in pregnancy or breastfeeding. Anti-exenatide antibodies develop in a substantial minority of patients and at high titres can blunt glycaemic response.